Pulmovant to present phase 2 mosliciguat study results Tuesday
Pulmovant, a clinical-stage biotech firm and Roivant subsidiary, will unveil Phase 2 results of its mosliciguat study on pulmonary hypertension linked to interstitial lung disease. The data will be unveiled at the European Respiratory Society International Congress 2026. Marc Humbert, a leading expert in the field, will deliver the presentation at 12:15 CEST (6:15 a.m. ET) on September 8, 2026.
The Phase 2 PHOCUS trial is a global, double-blind study involving 135 adult patients. It aims to evaluate the drug's safety and effectiveness. Pulmovant is also studying mosliciguat in combination with inhaled treprostinil in a Phase 2 PHACTOR trial. Inhaled mosliciguat demonstrated a mean peak reduction of up to 38% in pulmonary vascular resistance in a previous Phase 1b study.
Pulmonary hypertension associated with interstitial lung disease impacts approximately 200,000 patients in the U.S. and Europe.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
